Anzeige
Mehr »
Dienstag, 28.10.2025 - Börsentäglich über 12.000 News
Automatisierung ist das neue Gold: Telescope Innovations erfindet Entdeckung von Medizin & Materialien neu!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG6G | ISIN: SE0000736415 | Ticker-Symbol: C5G
Stuttgart
27.10.25 | 07:51
2,460 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OREXO AB Chart 1 Jahr
5-Tage-Chart
OREXO AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,5202,67007:53

Aktuelle News zur OREXO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEarnings Call zu Orexo AB: Aktie bricht nach Umsatzverfehlung im dritten Quartal 2025 ein1
DoOrexo Q3 2025 slides: Revenue miss overshadows AmorphOX pipeline progress1
DoOrexo AB Q3 Loss Narrows1
DoOrexo AB: Orexo Q3 2025 Interim Report66Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with...
► Artikel lesen
01.10.Orexo AB: Orexo strengthens innovation and research with move to new premises53Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move...
► Artikel lesen
30.09.Orexo US Awarded $8M in Funding by BARDA1
OREXO Aktie jetzt für 0€ handeln
29.09.Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership284Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical...
► Artikel lesen
05.09.Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication860A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were...
► Artikel lesen
29.08.Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court343UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will...
► Artikel lesen
16.07.Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds1
16.07.Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest1
16.07.Orexo AB: Orexo Q2 2025 Interim Report2112025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK...
► Artikel lesen
02.06.Orexo to present clinical data for OX640 at the EAACI Congress269OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI...
► Artikel lesen
06.05.Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements1
06.05.Orexo AB: Orexo Q1 2025 Interim Report235Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency...
► Artikel lesen
10.04.Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology412The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations...
► Artikel lesen
06.02.Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report195Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of...
► Artikel lesen
10.01.Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis499OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical...
► Artikel lesen
17.12.24Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology522The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical...
► Artikel lesen
02.12.24Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis450Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1